The present invention relates to solid oral pharmaceutical compositions comprising ticagrelor or salts thereof. In particular, the present invention relates to solid oral pharmaceutical compositions comprising ticagrelor or salts thereof and at least one pharmaceutically acceptable excipient other than water-insoluble fillers. There is also provided a method of reducing the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) by using the solid oral pharmaceutical composition ticagrelor or salts thereof.